指南与共识银屑病与炎症性皮肤病

比利时银屑病管理建议:变化中的治疗格局

Belgian recommendations for managing psoriasis in a changing treatment landscape.
指南 / 共识 · J Eur Acad Dermatol Venereol · 2024-10-12

八位比利时银屑病领域皮肤科专家基于EuroGuiDerm和德国S2指南更新,采用准德尔菲法提出合理使用创新药物(生物制剂和小分子)的建议。内容涵盖重症银屑病新定义、达标治疗、老款生物制剂与生物类似药的使用、个体化给药及远程皮肤科的作用,并更新了比利时循证治疗建议(BETA-PSO)。

要点

  • 合理使用创新药物需平衡疗效与医疗资源可持续性
  • 应参考国际银屑病理事会重症定义与达标治疗理念
  • 老款生物制剂、生物类似药及个体化给药仍具应用价值

核心结论

  • 比利时专家提出在资源有限背景下合理使用生物制剂和小分子的建议,并更新BETA-PSO治疗建议。

研究设计与样本

  • 八位比利时银屑病经验丰富的皮肤科医生基于EuroGuiDerm和德国S2指南更新,开展准德尔菲法形成建议。

主要发现

  • 建议涉及国际银屑病理事会重症银屑病新定义、银屑病严重度定义及达标治疗概念。
  • 讨论了老款生物制剂类别、生物类似药及个体化给药的适当性。
  • 探讨了远程皮肤科在提供可持续、以患者为中心的银屑病护理中的作用。
  • 包含更新版比利时循证治疗建议(BETA-PSO),反映近期数据和药物获批。

关键数值与推荐

  • 推荐反映临床医生使用系统和生物制剂治疗银屑病的最佳实践。
  • 提供关于可持续和高效处方这些药物的指导。

临床怎么用

  • 临床医生可参考本建议在系统和生物制剂治疗中合理选择药物与给药方式。
  • 可结合远程皮肤科手段优化银屑病长期管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeted biologic drugs and small molecules have transformed the psoriasis treatment landscape in recent years. The Belgian healthcare system, in common with many others across Europe, must balance the burgeoning use of these transformative, yet expensive, drugs with the sustainable use of limited resources. Drawing on recent updates to the EuroGuiDerm and the German S2 psoriasis guidelines, eight Belgian dermatologists experienced in treating patients with psoriasis undertook a quasi-Delphi initiative to provide perspectives on the current opportunities and challenges in psoriasis. This update focuses on responsible ways to rationalize the use of innovative treatments (e.g. biologics and small molecules). Inherently, this required viewpoints on the International Psoriasis Council's new definition of severe psoriasis, defining psoriasis severity and the concept of treating to target. It discusses the appropriateness of using older biologics classes, biosimilars and personalized dosing and lastly, how teledermatology may play a role in providing sustainable, patient-centric psoriasis care. In addition, this manuscript includes the updated Belgian evidence-based treatment advice in psoriasis (BETA-PSO) to reflect recent data and drug approvals. The recommendations reflect the best practices for clinicians when using systemic and biologic therapies to treat patients with psoriasis and offer guidance on how they may prescribe these drugs sustainably and efficiently.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Speeckaert R, Nikkels AF, Lambert J, et al. Belgian recommendations for managing psoriasis in a changing treatment landscape. J Eur Acad Dermatol Venereol. 2024. PMID: 39394848. doi:10.1111/jdv.20367

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。